Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torcetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torcetrapib SCHEMBL3203259 | 1.00 | CETP (0.86) | CETP | |
| Torcetrapib SCHEMBL3198126 | 1.00 | CETP (0.86) | CETP | |
| Torcetrapib SCHEMBL3187095 | 0.97 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3185801 | 0.97 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187101 | 0.97 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3188377 | 0.96 | CETP (0.79) | CETP | |
| Torcetrapib SCHEMBL3195597 | 0.94 | CETP (0.81) | CETP | |
| Torcetrapib SCHEMBL3205156 | 0.94 | CETP (0.81) | CETP | |
| Torcetrapib SCHEMBL3195589 | 0.94 | CETP (0.81) | CETP | |
| Torcetrapib SCHEMBL3204358 | 0.93 | CETP (0.79) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029716-A1 | NOVEL 1,2,3,4- TETRAHYDROQUINOLINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2007120621-A2 | NONEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029716-A1 | NOVEL 1,2,3,4- TETRAHYDROQUINOLINE DERIVATIVES | CETP, CES1, NPC1 | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.